CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy (Siège social : 29 avenue du Maréchal de Lattre de Tassigny, CO 60034, 54035 NANCY CEDEX
Hôpital Central : 29 Avenue du Maréchal de Lattre de Tassigny, 54035 Nancy
Hôpitaux de Brabois / Enfants : Rue du Morvan, 54500 Vandœuvre-lès-Nancy
Maternité régionale :10 Avenue Dr Heydenreich, 54000 Nancy - France)
UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
Abstract : Purpose: To assess the prognostic value of interim 18 F-fluorodeoxyglucose (FDG)-PET analysis using decrease in maximum standardized uptake value (SUVmax) versus visual analysis in patients with multiple myeloma. Patients and Methods: We evaluated the prognostic value of FDG-PET after three cycles of lenalidomide, bortezomib, and dexamethasone (RVD) in patients with FDG-avid multiple myeloma included in the French prospective multicenter IMAJEM study. All images were centrally reviewed and interpreted using visual criteria and maximal standardized uptake value reduction (DSUVmax). Known prognostic factors, such as the revised International Staging System and biochemical response after three cycles of chemotherapy, were also evaluated. Results: In the multivariate analysis, only DSUVmax [P < 0.001, HR ¼ 5.56; 95% confidence interval (CI), 1.96-15.81] and biochemical response after three cycles of RVD (P ¼ 0.025, HR ¼ 0.29; 95% CI, 0.1-0.85) appeared as independent prognostic factors, with a more discriminative HR for DSUVmax. DSUVmax analysis (>-25% vs.-25%) identified patients with improved median progression-free survival (22.6 months and not reached, respectively). Conclusions: DSUVmax appears to be a powerful tool for the prediction of long-term outcome in patients with FDG-avid multiple myeloma. Other prospective studies are needed to further validate this prognostic biomarker.
https://www.hal.inserm.fr/inserm-01934540 Contributor : Elizabeth BernardoConnect in order to contact the contributor Submitted on : Monday, November 26, 2018 - 9:20:33 AM Last modification on : Wednesday, April 27, 2022 - 3:58:01 AM Long-term archiving on: : Wednesday, February 27, 2019 - 12:56:29 PM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed
until : jamais
Clément Bailly, Thomas Carlier, Bastien Jamet, Thomas Eugène, Cyrille Touzeau, et al.. Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study. Clinical Cancer Research, American Association for Cancer Research, 2018, 24 (21), pp.5219 - 5224. ⟨10.1158/1078-0432.ccr-18-0741⟩. ⟨inserm-01934540⟩